Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights Aug 09, 2024
Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024 Aug 06, 2024
Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027 Jul 25, 2024
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma Jul 25, 2024
Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Jul 05, 2024
Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Jul 02, 2024
Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab Jul 02, 2024
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission Jun 24, 2024
